JP2024511315A5 - - Google Patents
Info
- Publication number
- JP2024511315A5 JP2024511315A5 JP2023554808A JP2023554808A JP2024511315A5 JP 2024511315 A5 JP2024511315 A5 JP 2024511315A5 JP 2023554808 A JP2023554808 A JP 2023554808A JP 2023554808 A JP2023554808 A JP 2023554808A JP 2024511315 A5 JP2024511315 A5 JP 2024511315A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- composition according
- amino acid
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159059P | 2021-03-10 | 2021-03-10 | |
| US63/159,059 | 2021-03-10 | ||
| PCT/US2022/019557 WO2022192404A1 (en) | 2021-03-10 | 2022-03-09 | Actrii-alk4 antagonists and methods of treating heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511315A JP2024511315A (ja) | 2024-03-13 |
| JP2024511315A5 true JP2024511315A5 (https=) | 2025-03-13 |
Family
ID=83228300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023554808A Pending JP2024511315A (ja) | 2021-03-10 | 2022-03-09 | Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240197902A1 (https=) |
| EP (1) | EP4304715A4 (https=) |
| JP (1) | JP2024511315A (https=) |
| KR (1) | KR20230169123A (https=) |
| CN (1) | CN117396224A (https=) |
| AU (1) | AU2022235082A1 (https=) |
| BR (1) | BR112023018256A2 (https=) |
| CA (1) | CA3211515A1 (https=) |
| MX (1) | MX2023010442A (https=) |
| WO (1) | WO2022192404A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41920B1 (fr) * | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| DK3496739T3 (da) * | 2016-07-15 | 2021-05-10 | Acceleron Pharma Inc | Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension |
| CA3039573A1 (en) * | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
| GB201620119D0 (en) * | 2016-11-29 | 2017-01-11 | Pharmafox Therapeutics Ag | Compounds |
| JP7669291B2 (ja) * | 2019-05-30 | 2025-04-28 | アクセレロン ファーマ インコーポレーテッド | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
| US20230174620A1 (en) * | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| JP2023534127A (ja) * | 2020-06-17 | 2023-08-08 | アクセルロン ファーマ インコーポレイテッド | ＡｃｔＲＩＩ－ＡＬＫ４アンタゴニストおよび心不全を処置する方法 |
-
2022
- 2022-03-09 JP JP2023554808A patent/JP2024511315A/ja active Pending
- 2022-03-09 AU AU2022235082A patent/AU2022235082A1/en active Pending
- 2022-03-09 BR BR112023018256A patent/BR112023018256A2/pt unknown
- 2022-03-09 KR KR1020237034038A patent/KR20230169123A/ko active Pending
- 2022-03-09 CN CN202280034554.6A patent/CN117396224A/zh active Pending
- 2022-03-09 EP EP22767900.8A patent/EP4304715A4/en active Pending
- 2022-03-09 CA CA3211515A patent/CA3211515A1/en active Pending
- 2022-03-09 MX MX2023010442A patent/MX2023010442A/es unknown
- 2022-03-09 US US18/549,461 patent/US20240197902A1/en active Pending
- 2022-03-09 WO PCT/US2022/019557 patent/WO2022192404A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508068A5 (https=) | ||
| US20210009696A1 (en) | Trispecific antagonists | |
| JP2023534127A5 (https=) | ||
| JP6640083B2 (ja) | 肺高血圧症を治療するための組成物および方法 | |
| JP2019511222A5 (https=) | ||
| JP2020535184A5 (https=) | ||
| JP7512272B2 (ja) | Ａｌｋ２抗体及びその使用方法 | |
| UA125337C2 (uk) | Ctla4-зв'язувальні речовини | |
| JP2021511826A5 (https=) | ||
| JP2014524903A5 (https=) | ||
| JP2016536369A5 (https=) | ||
| JP2024511316A5 (https=) | ||
| JP2023524811A5 (https=) | ||
| KR20150109386A (ko) | 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체 | |
| BR112021004686A2 (pt) | proteínas de ligação de antígeno anti-flt3 melhoradas | |
| KR20160145166A (ko) | 혈관 내피 성장 인자 vegf를 중화시키는 vnar 재조합 단일클론 항체 | |
| JP2024511315A5 (https=) | ||
| JP2024544057A5 (https=) | ||
| JP2024542823A5 (https=) | ||
| TW201210615A (en) | Dengue vaccine, medicinal composition comprising the same, nucleotide sequence, and antibody composition | |
| JP7830567B2 (ja) | ペプチドおよびその医学的使用 | |
| TW201210614A (en) | Dengue vaccine, medicinal composition comprising the same, and nucleotide sequence | |
| RU2023123907A (ru) | Антагонисты actrii-alk4 и способы лечения сердечной недостаточности | |
| RU2023123916A (ru) | Антагонисты actrii-alk4 и способы лечения сердечной недостаточности | |
| US11634496B2 (en) | C-MET agonistic antibody and use thereof |